CDC Backs Twice-Yearly Injectable for HIV Prevention
The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir (Yeztugo) for HIV pre-exposure prophylaxis (PrEP), but will that ensure the treatment’s place in the nation’s health plan formularies? “[Lenacapavir] is a highly effective and safe PrEP option administered every 6 months, which provides the potential […]
Long-Acting HIV Drug Promising for Treatment-Naive Patients
Lenacapavir (Sunlenca) given every 26 weeks along with daily antiretroviral therapy (ART) suppressed HIV on par with conventional regimens in the first-line setting in the phase II CALIBRATE trial. Viral suppression to fewer than 50 copies/mL at week 54 was 85-90% across all three groups given the drug whether orally or subcutaneously every 26 weeks […]
Novel Capsid Inhibitor Approved for Super-Refractory HIV
The FDA approved lenacapavir (Sunlenca) in combination with antiretroviral therapy (ART) for heavily pretreated HIV-1 patients with drug-resistant infections, and for those who cannot tolerate other available options. Lenacapavir, a first-in-class long-acting HIV capsid inhibitor, is initially administered via oral tablets (300 mg) and subcutaneous shots (463.5 mg/1.5 mL), which are then followed by maintenance […]